Billions of dollars in U.S. biosimilar erosion to AbbVie’s blockbuster immunology drug Humira is no match for its rising ...
Feb 4 (Reuters) - AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and ...
Investor's Business Daily on MSN
AbbVie pummeled after delivering a fourth-quarter beat — on the back of Humira
Investors pummeled AbbVie stock Wednesday after the company delivered a fourth-quarter sales beat, thanks to Humira.
AbbVie (ABBV) stock falls even as the company beat Street foecasts with its Q4 2025 results and issued a better than expected ...
AbbVie (ABBV) stock slides 7% as its former best seller Humira drives Q4 2025 beat not newer immunology drugs. Read more here.
Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday, when AbbVie ...
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” ...
Despite AbbVie exceeding expectations for the last year and its forecast for 2026, its stock still fell in trading this morning as investors zeroed in on vulnerabilities in its tentpole drugs.
AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results